Krystal Biotech, Inc. 10-Q

ITEM 1. FINANCIAL STATEMENTS Krystal Biotech, Inc. Condensed Consolidated Balance Sheets (unaudited) (In thousands, except share and per share data) September 30, 2023 December 31, 2022 Assets Current assets Cash and cash equivalents $ 373,241 $ 161,900 Short-term investments 188,828 217,271 Accounts receivable, net 9,316 — Inventory 5,278 — Prepaid expenses and other current assets 5,465 4,608 Total current assets 582,128 383,779 Property and equipment, net 164,029 161,684 Long-term investments 36,548 4,621 Right-of-use assets 7,360 8,042 Other non-current assets 285 324 Total assets $ 790,350 $ 558,450 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 4,340 $ 3,981 Current portion of lease liability 1,501 1,561 Accrued expenses and other current liabilities 21,742 23,305 Total current liabilities 27,583 28,847 Lease liability 6,819 7,372 Total liabilities 34,402 36,219 Commitments and contingencies (Note 7) Stockholders' equity Common stock; $ 0.00001 par value; 80,000,000 shares authorized at September 30, 2023 and December 31, 2022; 28,194,655 shares issued and outstanding at September 30, 2023; and 25,763,743 shares issued and outstanding at December 31, 2022 — — Additional paid-in capital 1,034,849 803,718 Accumulated other comprehensive loss ( 382 ) ( 728 ) Accumulated deficit ( 278,519 ) ( 280,759 ) Total stockholders' equity 755,948 522,231 Total liabilities and stockholders' equity $ 790,350 $ 558,450 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Krystal Biotech, Inc. Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except share and per share data) 2023 2022 2023 2022 Product revenues, net $ 8,556 $ — $ 8,556 $ — Expenses: Cost of goods sold 223 — 223 — Research and development 10,629 11,516 35,061 31,720 Selling, general, and administrative 23,697 19,935 73,637 53,705 Litigation settlement — — 12,500 25,000 Total operating expenses 34,549 31,451 121,421 110,425 (Loss) from operations ( 25,993 ) ( 31,451 ) ( 112,865 ) ( 110,425 ) Other income: Gain from sale of priority review voucher 100,000 — 100,000 — Interest and other income, net 6,740 1,601 15,105 2,502 Net income (loss) $ 80,747 $ ( 29,850 ) 2,240 ( 107,923 ) Unrealized (loss) gain on available-for-sale securities and currency translation adjustment ( 146 ) 70 346 ( 1,312 ) Comprehensive income (loss) $ 80,601 $ ( 29,780 ) $ 2,586 $ ( 109,235 ) Net income (loss) per common share: Basic $ 2.88 $ ( 1.17 ) $ 0.08 $ ( 4.24 ) Diluted $ 2.79 $ ( 1.17 ) $ 0.08 $ ( 4.24 ) Weighted-average common shares outstanding: Basic 28,042,130 25,619,125 26,812,278 25,428,097 Diluted 28,892,226 25,619,125 27,384,539 25,428,097 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Krystal Biotech, Inc. Condensed Consolidated Statements of Stockholders' Equity (unaudited) Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Total Stockholders' (In thousands, except shares) Shares Amount Capital Loss Deficit Equity Balances at January 1, 2023 25,763,743 $ — $ 803,718 $ ( 728 ) $ ( 280,759 ) $ 522,231 Issuance of common stock, net 42,021 — 2,208 — — 2,208 Shares surrendered for taxes ( 9,551 ) — ( 749 ) — — ( 749 ) Stock-based compensation expense — — 10,599 — — 10,599 Unrealized gain on investments and other — — — 574 — 574 Net loss — — — — ( 45,297 ) ( 45,297 ) Balances at March 31, 2023 25,796,213 $ — $ 815,776 $ ( 154 ) $ ( 326,056 ) $ 489,566 Issuance of common stock, net 2,178,703 — 185,397 — — 185,397 Stock-based compensation expense — — 11,443 — — 11,443 Unrealized (loss) on investments and other — — — ( 82 ) — ( 82 ) Net loss — — — — ( 33,210 ) ( 33,210 ) Balances at June 30, 2023 27,974,916 $ — $ 1,012,616 $ ( 236 ) $ ( 359,266 ) $ 653,114 Issuance of common stock, net 219,739 — 13,511 — — 13,511 Stock-based compensation expense — — 8,722 — — 8,722 Unrealized (loss) on investments and other — — — ( 146 ) — ( 146 ) Net income — — — — 80,747 80,747 Balances at September 30, 2023 28,194,655 $ — $ 1,034,849 $ ( 382 ) $ ( 278,519 ) $ 755,948 Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Total Stockholders' (In thousands, except shares) Shares Amount Capital (Loss) Deficit Equity Balances at January 1, 2022 25,207,985 $ — $ 734,523 $ ( 163 ) $ ( 140,784 ) $ 593,576 Issuance of common stock, net 1,475 — 55 — — 55 Shares surrendered for taxes and forfeitures ( 10,379 ) — ( 649 ) — — ( 649 ) Stock-based compensation expense — — 6,571 — — 6,571 Unrealized (loss) on investments and other — — — ( 1,034 ) — ( 1,034 ) Net loss — — — — ( 49,965 ) ( 49,965 ) Balances at March 31, 2022 25,199,081 $ — $ 740,500 $ ( 1,197 ) $ ( 190,749 ) $ 548,554 Issuance of common stock, net 472,706 — 30,748 — — 30,748 Shares forfeited ( 7,500 ) — — — — — Stock-based compensation expense — — 8,335 — — 8,335 Unrealized (loss) on investments and other — — — ( 348 ) — ( 348 ) Net loss — — — — ( 28,108 ) ( 28,108 ) Balances at June 30, 2022 25,664,287 $ — $ 779,583 $ ( 1,545 ) $ ( 218,857 ) $ 559,181 Issuance of common stock, net 45,377 — 2,176 — — 2,176 Stock-based compensation expense — — 9,195 — — 9,195 Unrealized gain on investments and other — — — 70 — 70 Net loss — — — — ( 29,850 ) ( 29,850 ) Balances at September 30, 2022 25,709,664 $ — $ 790,954 $ ( 1,475 ) $ ( 248,707 ) $ 540,772 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 Krystal Biotech, Inc. Condensed Consolidated Statements of Cash Flows (unaudited) Nine Months Ended September 30, (In thousands) 2023 2022 Operating Activities Net income (loss) $ 2,240 $ ( 107,923 ) Adjustments to reconcile net income (loss) to net cash (used in) operating activities Gain from sale of priority review voucher ( 100,000 ) — Depreciation and amortization 2,569 2,966 Stock-based compensation expense 30,080 23,678 Loss on disposals of fixed assets — 22 Other, net ( 4,290 ) ( 224 ) Changes in operating assets and liabilities Accounts receivable ( 9,316 ) — Inventory ( 3,983 ) — Prepaid expenses and other current assets ( 137 ) 1,031 Other non-current assets ( 48 ) ( 31 ) Lease liability ( 603 ) ( 459 ) Accounts payable 121 ( 316 ) Accrued expenses and other current liabilities 1,795 3,016 Net cash (used in) operating activities ( 81,572 ) ( 78,240 ) Investing Activities Proceeds from sale of priority review voucher 100,000 — Purchases of property and equipment ( 9,952 ) ( 47,762 ) Purchases of investments ( 425,870 ) ( 214,712 ) Proceeds from maturities of investments 428,620 153,599 Net cash provided by (used in) investing activities 92,798 ( 108,875 ) Financing Activities Issuance of common stock, net of issuance costs 200,880 32,927 Taxes paid related to settlement of restricted stock awards ( 749 ) ( 649 ) Net cash provided by financing activities 200,131 32,278 Effect of exchange rate changes on cash and cash equivalents ( 16 ) — Net increase (decrease) in cash and cash equivalents 211,341 ( 154,837 ) Cash and cash equivalents at beginning of period 161,900 341,246 Cash and cash equivalents at end of period $ 373,241 $ 186,409 Supplemental Disclosures of Non-Cash Investing and Financing Activities Unpaid purchases of property and equipment included in accounts payable and accrued expenses $ 11,103 $ 15,305 Initial recognition of right-of-use assets $ — $ 1,556 The accompanying notes are an integral part of these condensed consolidated financial statements. 6 Krystal Biotech, Inc. Notes to Condensed Consolidated Financial Statements (unaudited) 1. Organization Krystal Biotech, Inc. (the “Company,” or “we” or other similar pronouns) commenced operations in April 2016. In March 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. In June 2018, the Company incorporated a wholly-owned subsidiary in Australia for the purpose of undertaking preclinical and clinical studies in Australia. In April 2019, the Company incorporated Jeune Aesthetics, Inc. (“Jeune Aesthetics”), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. In January 2022, August 2022, December 2022, and August 2023, the Company incorporated wholly-owned subsidiaries in Switzerland, Netherlands, France, and Germany, respectively, for the purpose of establishing initial operations in Europe for the commercialization of the Company’s product pipeline. We are a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Our approach leverages our patented platform that is based on an engineered Herpes Simplex Virus-1 (“HSV-1”) vector to deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the transgene to treat the disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional’s office or in the patient’s home by a healthcare professional. Our innovative technology platform is supported by two in-house, commercial scale Current Good Manufacturing Practices ("CGMP") manufacturing facilities. On May 19, 2023, the Company received U.S. Food and Drug Administration (“FDA”) approval for its first product, VYJUVEK ® (“VYJUVEK”) for the treatment of Dystrophic Epidermolysis Bullosa (“DEB”) in patients six months or older. Additionally, the Company received a Rare Pediatric Disease Priority Review Voucher (“PRV”) in connection with the VYJUVEK approval. VYJUVEK became commercially available upon approval, and we began generating revenue from VYJUVEK product sales in 3Q 2023. Liquidity As of September 30, 2023, the Company had an accumulated deficit of $ 278.5 million. As the Company continues to incur operating losses, a transition to operating profitability is dependent upon the successful commercialization of VYJUVEK as well as successful development, approval, and commercialization of its other product candidates and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve operating profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through its on hand cash and cash equivalents, revenue generated from the sale of VYJUVEK, the sale of equity, debt financings, and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all. The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to commercialize product candidates. The Company expects to incur significant costs to further its pipeline and to expand its commercialization capabilities in advance of the potential global regulatory approvals of VYJUVEK. The Company believes that its cash, cash equivalents and short-term investments of approximately $ 562.1 million as of September 30, 2023 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. 7 The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission (“SEC”) on February 27, 2023. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates in the period these variances become known. Estimates are used in the following areas, among others: variable consideration associated with revenue recognition, stock-based compensation expense, accrued expenses, and the valuation allowance included in the deferred income tax calculation. Segment and Geographical Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products. Cash, Cash Equivalents and Investments Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90 days or less at the date of purchase. Investments with maturities of less than one year are classified as short-term investments on the condensed consolidated balance sheets and consist of commercial paper, corporate bonds, and U.S. government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the condensed consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on investments is also classified as short-term investments on the condensed consolidated balance sheets. As our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders’ equity in the condensed consolidated balance sheets. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest and other income, net, in the condensed consolidated statements of operations and comprehensive income (loss). Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows: • Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities. • Level 2 — Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Valuations based on inputs that are both significant to the fair value measurement and unobservable. 8 To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented. The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, accounts receivable, net, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company’s condensed consolidated financial statements, approximate fair value, primarily due to their short maturities. Our available-for-sale, short-term and long-term investments are considered to be Level 2 financial instruments. Revenue Recognition The Company sells VYJUVEK to a limited number of specialty pharmacies (“SPs”) that mix the medication and administer it to patients in the patient’s home by a healthcare professional and a single specialty distributor (“SD”), that distributes VYJUVEK to hospitals and outpatient clinics where patients are administered the medication at a healthcare professional’s office. The Company recognizes product revenue under ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, the Company is required to complete the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes revenue when the customer obtains control of the product, which occurs at a point in time, upon delivery to the customer. Sales and other taxes collected concurrent with revenue-producing activities are excluded from revenue. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring VYJUVEK and is generally based upon a list or fixed price less allowances for returns, rebates and discounts. The Company’s payment terms are generally 30 to 60 days from the invoice date. Variable Consideration Product revenues is recorded at the net sales price, or transaction price, upon delivery and transfer of control to the customer, and includes an estimate of variable consideration, which results from discounts, rebates, and returns that are offered within contracts between the Company and its customers. – Prompt Pay Discounts: As an incentive for prompt payment, the Company offers a cash discount to customers. The Company estimates accrued prompt pay discounts using the most likely amount method. The Company expects that all eligible customers will comply with the contractual terms to earn the discount. The Company records the discount as an allowance against accounts receivable, net and a reduction of revenue. – Government Rebates: The Company participates in certain government rebate programs including Medicaid. The Company estimates accrued government rebates using the expected value method. The Company accrues estimated rebates based on estimated percentages of VYJUVEK prescribed to qualified patients, estimated rebate percentages and estimated levels of inventory in the distribution channel that will be prescribed to qualified patients and records the rebates as a reduction of revenue. Accrued government rebates are recorded as a reduction of revenue and are included in other accrued liabilities on the condensed consolidated balance sheets. – Commercial Rebates: The Company participates in certain commercial rebate programs. Under these rebate programs, the Company pays a rebate to the commercial entity or third-party administrator of the program. Accrued commercial rebates are estimated using the expected value method. The Company accrues estimated rebates based on contract prices, estimated percentages of VYJUVEK that will be prescribed to qualified patients and estimated levels of inventory in the distribution channel. Accrued commercial rebates are recorded as a reduction of revenue and are included in other accrued liabilities on the condensed consolidated balance sheets. – Copay Assistance: The Company provides copay assistance to qualified patients, helping them meet copay obligations to their insurance provider. The Company reimburses pharmacies for this discount through third-party vendors. The Company estimates copay assistance costs using the expected value method. The estimate is based on contract prices, estimated percentages of VYJUVEK that will be prescribed to qualified patients, average assistance paid based on reporting from third-party vendors and estimated levels of inventory in the distribution channel. Copay assistance costs are recorded as reductions to revenue and are accrued in other accrued liabilities on the condensed consolidated balance sheets. 9 – Returns: The Company offers SPs and SDs limited return rights relating to product damage or defect and based on these provisions, the Company believes that there will be minimal returns. Variable consideration is estimated and reduces the transaction price to reflect the Company’s best estimate of the amount of consideration to which the Company is entitled based on the terms of the contracts and are recorded in the same period the related product revenues is recognized. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is considered probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates in the period these variances become known. Cost of Goods Sold Cost of goods sold includes direct and indirect costs related to the manufacturing of VYJUVEK. These costs consist of manufacturing costs, personnel costs including stock-based compensation, facility costs, and other indirect overhead costs. Cost of goods sold may also include period costs related to certain manufacturing services and inventory adjustment charges. Accounts Receivable Accounts receivable is recorded net of allowances for prompt payment discounts, returns, and credit losses. The Company estimates an allowance for credit losses by considering factors such as credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. As of September 30, 2023, the credit profiles for the Company’s customer was deemed to be in good standing, and as such an allowance for credit losses was not recorded. Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, short-term investments, long-term investments, and accounts receivable, net. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company’s accounts receivable, net and marketable securities, which primarily consist of U.S. government agency securities and treasuries, equity securities, corporate bonds and commercial paper, potentially subject the Company to concentrations of credit risk. The Company had one customer for the three and nine months ended September 30, 2023 and no product revenues for the three and nine months ended September 30, 2022. The Company has no financial instruments with off-balance sheet risk of loss. Inventories The Company capitalizes inventory costs associated with products when future economic benefit is expected to be realized. These costs consist of raw materials, manufacturing-related costs, personnel costs including stock-based compensation, facility costs, and other indirect overhead costs. Prior to receiving FDA approval for VYJUVEK in May 2023, the Company expensed costs related to inventory for clinical and pre-commercial purposes directly to research and development expense. Following the FDA’s approval of VYJUVEK, the Company began capitalizing inventory related to commercialized products held for sale, in-process of production for sale, and raw materials to be used in the manufacturing of inventory. The Company values its inventories at the lower-of-cost and net realizable value, on a first-in, first-out (“FIFO”) basis. The Company adjusts the net realizable value of any excess, obsolete or unsalable inventories in the period in which an impairment is identified. For the three and nine months ended September 30, 2023 and 2022, there were no inventory impairment adjustments. As of September 30, 2023, the Company recorded $ 5.3 million of inventory, consisting of raw materials, work-in-process, and finished goods within inventory on the Company’s condensed consolidated balance sheets. Property and Equipment, net Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows: 10 Buildings and building improvements 7 - 47 years Computer equipment and software 3 - 7 years Manufacturing equipment 3 - 20 years Laboratory equipment 3 - 15 years Furniture and fixtures 3 - 7 years Leasehold improvements lesser of useful life or remaining life of lease The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives. Construction in progress is not depreciated until the asset is placed in service. Impairment of Long-Lived Assets The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable. In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to an amount by which the net book value exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company has no t identified any triggering events or recognized any impairment losses for the three and nine months ended September 30, 2023 and 2022. Leases The Company accounts for its lease agreements in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification, or ASC, Topic 842, Leases . Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease liabilities represent the commitment to make lease payments arising from the lease. Right-of-use lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company’s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its condensed consolidated balance sheets and to account for lease and non-lease components of its operating leases as a single component. Research and Development Expenses Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs. The Company estimates contract research and manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company’s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are capitalized within prepaid expenses and other current assets on the condensed consolidated balance sheets. The capitalized amounts are expensed as the related goods are delivered or the services are performed. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with third-party service providers and the Company’s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. 11 Stock-Based Compensation Expense The Company applies the fair value recognition provisions of FASB, ASC Topic 718, Compensation—Stock Compensation ("ASC 718"), to account for stock-based compensation. Compensation costs related to equity awards granted are based on the estimated fair value of the awards on the date of grant. ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense for stock options, restricted stock awards, and restricted stock units is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense for performance-based restricted stock units is recognized for the awards that are probable of vesting over the service period of the award. On a quarterly basis, management estimates the probable number of performance-based restricted stock units that would vest until such time that the ultimate achievement of the performance criteria are known. The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i) the expected stock price volatility; (ii) the expected term of the award; (iii) the risk-free interest rate; and (iv) expected dividends. The Company estimates stock price volatility by using its own historical data. The expected term of the Company’s stock options is estimated using the “simplified” method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. Comprehensive Income (Loss) Comprehensive income (loss) is defined as the change in equity during a period from transactions from non-owner sources. Unrealized gains or losses on available-for-sale securities and foreign currency translation are components of other comprehensive gains or losses and are presented net of taxes. We record reclassifications from other comprehensive gains or losses to interest and other income, net on the condensed consolidated statements of operations related to realized gains on sales of available-for-sale securities. The Company reviews its securities quarterly to determine whether an other-than-temporary impairment has occurred. The Company determined that there were no other-than-temporary impairments during the three and nine months ended September 30, 2023 and 2022. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB that the Company adopts as of the specified effective date. There were no recently adopted accounting pronouncements that had a material impact on the Company’s condensed consolidated financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company’s condensed consolidated financial statements. 3. Revenue Recognition The Company began commercial marketing and sales of VYJUVEK throughout the United States and began recognizing revenue in 3Q 2023. For the three and nine months ended September 30, 2023 and 2022, the Company recognized net product revenues of $ 8.6 million and zero , respectively. Accounts receivable balances were $ 9.3 million and zero as of September 30, 2023 and December 31, 2022, respectively. The following table summarizes changes in allowances and discounts for the three months ended September 30, 2023 (in thousands): Rebates Prompt Pay Other Accruals Total Balance as of June 30, 2023 $ — $ — $ — $ — Provision 920 195 78 1,192 Payments/Credits — ( 5 ) — ( 5 ) Balance, as of September 30, 2023 $ 920 $ 190 $ 78 $ 1,187 12 4. Net Income (Loss) Per Share Attributable to Common Stockholders Basic net income (loss) per share attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards and restricted stock units. There were 378,299 and 1,277,313 common share equivalents, in the form of stock options, that have been excluded of from the calculation of diluted net income (loss) per common share for the three and nine months ended September 30, 2023, respectively, as their effect would be anti-dilutive. There were 3,565,110 common share equivalents outstanding in the form of stock options and unvested restricted stock awards as of September 30, 2022 that were excluded from the calculation of diluted net income (loss) per common share as their effect would be anti-dilutive. Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except share and per share data) 2023 2022 2023 2022 Numerator: Net income (loss) $ 80,747 $ ( 29,850 ) $ 2,240 $ ( 107,923 ) Denominator: Weighted-average basic common shares 28,042,130 25,619,125 26,812,278 25,428,097 Dilutive effect of stock options and unvested restricted stock 850,096 — 572,261 — Weighted-average diluted common shares 28,892,226 25,619,125 27,384,539 25,428,097 Net income (loss) per common share — Basic $ 2.88 $ ( 1.17 ) $ 0.08 $ ( 4.24 ) Net income (loss) per common share — Diluted $ 2.79 $ ( 1.17 ) $ 0.08 $ ( 4.24 ) 5. Fair Value Instruments The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of September 30, 2023 and December 31, 2022, respectively (in thousands): September 30, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized (Losses) Aggregate Fair Value Cash and Cash Equivalents Short-term Marketable Securities (1) Long-term Marketable Securities (2) Level 1: Cash and cash equivalents $ 373,241 $ — $ — $ 373,241 $ 373,241 $ — $ — Subtotal 373,241 — — 373,241 373,241 — — Level 2: Commercial paper 43,496 1 ( 9 ) 43,488 — 43,488 — Corporate bonds 70,465 4 ( 201 ) 70,268 — 56,463 13,805 U.S. government agency securities 111,635 225 ( 240 ) 111,620 — 88,877 22,743 Subtotal 225,596 230 ( 450 ) 225,376 — 188,828 36,548 Total $ 598,837 $ 230 $ ( 450 ) $ 598,617 $ 373,241 $ 188,828 $ 36,548 13 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized (Losses) Aggregate Fair Value Cash and Cash Equivalents Short-term Marketable Securities (1) Long-term Marketable Securities (2) Level 1: Cash and cash equivalents $ 161,900 $ — $ — $ 161,900 $ 161,900 $ — $ — Subtotal 161,900 — — 161,900 161,900 — — Level 2: Commercial paper 63,624 5 ( 23 ) 63,606 — 63,606 — Corporate bonds 82,241 13 ( 419 ) 81,835 — 77,214 4,621 U.S. government agency securities 76,683 161 ( 393 ) 76,451 — 76,451 — Subtotal 222,548 179 ( 835 ) 221,892 — 217,271 4,621 Total $ 384,448 $ 179 $ ( 835 ) $ 383,792 $ 161,900 $ 217,271 $ 4,621 (1) The Company’s short-term marketable securities mature in one year or less. (2) The Company's long-term marketable securities mature between one year and two years . See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company’s fair value measurements. 6. Balance Sheet Components Property and Equipment, Net Property and equipment, net consist of the following (in thousands): September 30, 2023 December 31, 2022 Building and building improvements 72,193 — Construction in progress $ 56,074 $ 131,331 Leasehold improvements 24,835 24,217 Manufacturing equipment 16,827 9,783 Laboratory equipment 2,339 2,089 Furniture and fixtures 1,518 957 Computer equipment and software 982 100 Total property and equipment 174,768 168,477 Accumulated depreciation ( 10,739 ) ( 6,793 ) Property and equipment, net $ 164,029 $ 161,684 Depreciation expense was $ 1.2 million and $ 3.5 million for the three and nine months ended September 30, 2023 and $ 669 thousand and $ 1.6 million for the three and nine months ended September 30, 2022, respectively. On March 27, 2023, the Company received the permanent occupancy permit for its second commercial scale CGMP facility, ASTRA, which allowed the Company to begin utilizing certain portions of the building. As a result, certain assets relating to ASTRA were reclassified from construction in progress to leasehold improvements, manufacturing equipment, buildings and building improvements, furniture and fixtures, or computer equipment and software during the first half of 2023. The Company placed additional portions of ASTRA into service during the three months ended September 30, 2023 as it was determined that additional assets were ready for their intended use. As certain building improvements are not yet complete and certain qualification activities are still underway, the Company will continue to hold the remaining assets within construction in progress until validation has been completed and the assets are ready for their intended use. Validation of the facility is expected to be completed in 2023. 14 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): September 30, 2023 December 31, 2022 Accrued construction in progress $ 7,548 $ 11,452 Accrued payroll and benefits 7,033 6,781 Accrued professional fees 2,786 3,397 Other current liabilities 2,315 267 Accrued preclinical and clinical expenses 1,908 1,365 Accrued taxes 152 43 Total $ 21,742 $ 23,305 7. Commitments and Contingencies Agreements with Contract Research Organizations and Contract Manufacturing Organizations The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs primarily relate to the manufacturing of our cell and virus banks and for the manufacturing of our sterile gel that is mixed with in-house produced vectors as part of the final drug product for VYJUVEK. Agreements with third parties may also include research and development consulting activities, clinical-trial agreements, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage or pre-commercial products. The Company is obligated to make milestone payments under certain of these contracts. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The estimated remaining commitment as of September 30, 2023 under these agreements is approximately $ 2.7 million. The Company has incurred research and development expenses under these agreements of $ 1.9 million and $ 5.0 million for the three and nine months ended September 30, 2023, respectively, and $ 2.1 million and $ 5.1 million for the three and nine months ended September 30, 2022, respectively. ASTRA Contractual Obligations The Company has contracted with various third parties to complete and qualify our second CGMP facility, ASTRA. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of September 30, 2023 is $ 11.1 million and primarily relates to the remaining building improvements and certain qualification activities of the facility. The Company has included costs incurred to-date associated with the ongoing build-out of ASTRA within construction in progress, except for the assets of the facility that have been placed in service. As of September 30, 2023, Substantial Completion, as defined in the Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (the “Agreement”) with Whiting-Turner Contracting Company (“Whiting-Turner”), the construction manager for ASTRA, had not been achieved. Whiting-Turner’s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner’s work under the Agreement may not equate to the date of in-service for portions of ASTRA or the date of full facility completion of ASTRA. Legal Proceedings In May 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen") alleging breach of contract and misappropriation of trade secrets. On April 27, 2022, the Company and PeriphaGen entered into a final settlement agreement, and the Company paid PeriphaGen an upfront payment of $ 25.0 million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications. In accordance with the settlement agreement, on June 15, 2023, the Company paid PeriphaGen an additional $ 12.5 million following the FDA’s approval of VYJUVEK. The settlement agreement requires the Company to pay three additional $ 12.5 million contingent milestone payments upon reaching $ 100.0 million in total cumulative sales, $ 200.0 million in total cumulative sales and $ 300.0 million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of the Company products by the Company and its affiliates and licensees, as reported by the 15 Company in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $ 75.0 million, of which $ 37.5 million has been paid. The Company recorded the settlement payments of zero and $ 12.5 million for the three and nine months ended September 30, 2023, respectively, and zero and $ 25.0 million for the three and nine months ended September 30, 2022, respectively, under litigation settlement expense on the condensed consolidated statements of operations. As of September 30, 2023, the Company has not recorded an accrual for the remaining contingent milestone payments. The Company did no t receive insurance proceeds during the three and nine months ended September 30, 2023 and received zero and $ 768 thousand during the three and nine months ended September 30, 2022, respectively. The reimbursements have been recorded as a reduction to our legal fees included in selling, general, and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows. 8. Leases As of September 30, 2023, future minimum commitments under the Company’s operating leases with lease terms in excess of 12 months were as follows (in thousands): Operating Leases 2023 (remaining three months) $ 413 2024 1,539 2025 1,277 2026 1,277 2027 1,300 Thereafter 10,763 Future minimum operating lease payments $ 16,569 Less: Interest ( 8,249 ) Present value of lease liability $ 8,320 Supplemental condensed consolidated balance sheet information related to leases is as follows: September 30, 2023 December 31, 2022 Operating leases: Right-of-use assets $ 7,360 $ 8,042 Current portion of lease liability 1,501 1,561 Lease liability 6,819 7,372 Total lease liability $ 8,320 $ 8,933 Weighted average remaining lease term, in years 12.3 12.5 Weighted average discount rate 9.4 % 9.4 % The components of the Company's lease expense are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Lease cost: Operating lease expense $ 379 $ 399 $ 1,282 $ 1,200 Variable lease expense 62 48 150 168 Total lease expense $ 441 $ 447 $ 1,432 $ 1,368 16 9. Capitalization ATM Program On December 31, 2020, the Company entered into a sales agreement with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("2020 ATM Program"), under which the Company issued and sold from time to time through Cowen, acting as agent and/or principal, shares of its common stock, par value $ 0.0001 per share, having an aggregate offering price up to $ 150.0 million ("Placement Shares"). The issuance and sale of the Placement Shares were made pursuant to the Company's effective "shelf" registration statement on Form S-3 that was filed with the Securities and Exchange Commission (the “SEC”) on May 4, 2020 (the “2020 Shelf Registration Statement”). During the nine months ended September 30, 2022, the Company issued and sold 434,782 Placement Shares at a weighted average price of $ 69.00 per share for net proceeds of $ 29.1 million after deducting selling commissions of approximately $ 900 thousand. The Company’s 2020 Shelf Registration Statement expired on May 4, 2023, and the Company put in place a new at-the-market equity offering program under substantially the same terms as the 2020 ATM Program (the “New ATM Program”). Accordingly, on May 8, 2023, the Company entered into a new sales agreement with Cowen to issue and sell shares of the Company’s common stock having an aggregate offering price of up to $ 150.0 million (the “New Placement Shares”) from time to time, under which Cowen will act as the Company’s agent and/or principal. The New Placement Shares will be offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 filed with the SEC on April 6, 2023, and a prospectus supplement relating to the New Placement Shares that was filed with the SEC on May 8, 2023. During the quarter ended September 30, 2023 no shares of common stock were issued pursuant to the New ATM Program, resulting in $ 150.0 million available for issuance under the New ATM Program. 2023 Private Placement Offering On May 22, 2023 and May 23, 2023, the Company sold 1,720,100 and 9,629 shares of common stock, respectively, in a private placement to certain institutional investors at a price of $ 92.50 per share for aggregate net proceeds of $ 160.0 million. In addition, the Company entered into a Registration Rights Agreement with the investors (“Registration Rights Agreement”) that required the Company to file a registration statement with the SEC within 60 days of the date of the Registration Rights Agreement registering the resale of the shares of common stock issued in the private placement. On July 18, 2023, the Company filed the resale registration statement on Form S-3ASR with the SEC, which became effective upon filing. 10. Stock-Based Compensation In 2017, the Company adopted the 2017 IPO Stock Plan (the “Plan”), which governs the issuance of stock options and restricted stock to employees, certain non-employee consultants, and directors. Initially, the Company reserved 900 thousand shares for issuance under the Plan with an initial sublimit for incentive stock options of 900 thousand shares. On an annual basis, the amount of shares available for issuance under the Plan increases by an amount equal to four percent of the total outstanding shares as of the last day of the preceding calendar year. The sublimit of incentive stock options is not subject to the increase. The Company has historically granted stock options and restricted stock awards to its employees. In February 2023, the Company began issuing restricted stock units and performance-based restricted stock units to certain employees. Stock Options Options granted to employees and non-employees vest ratably over a four-year period and stock options granted to directors of the Company vest ratably over one -year to three -year periods. Stock options have a life of ten years . The Company granted 30,500 and 419,780 stock options to employees, non-employees, and directors of the Company during the three and nine months ended September 30, 2023 and 189,000 and 1,958,000 to employees, non-employees, and directors of the Company during the three and nine months ended September 30, 2022, respectively. 17 The following table summarizes the Company’s stock option activity: Stock Options Outstanding Weighted- average Exercise Price Weighted- average Remaining Contractual Life (Years) Aggregate Intrinsic Value (In thousands) (1) Outstanding at December 31, 2022 3,582,181 $ 61.50 8.7 $ 64,880 Granted 419,780 $ 91.38 Exercised ( 710,734 ) $ 57.98 Cancelled or forfeited ( 623,967 ) $ 64.19 Expired — $ — Outstanding at September 30, 2023 2,667,260 $ 66.04 8.2 $ 133,648 Exercisable at September 30, 2023 707,277 $ 55.51 7.1 $ 42,793 (1) Aggregate intrinsic value represents the difference between the closing stock price of our common stock on September 30, 2023 and the exercise price of outstanding in-the-money options. The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and nine months ended September 30, 2023 was $ 13.5 million and $ 41.4 million, respectively, and during the three and nine months ended September 30, 2022 was $ 1.3 million and $ 2.1 million, respectively. The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three and nine months ended September 30, 2023 was $ 85.93 and $ 62.87 , respectively, and during the three and nine months ended September 30, 2022 was $ 49.59 and $ 43.66 , respectively. There was $ 77.5 million of unrecognized stock-based compensation expense related to employees', non-employees', and directors’ option awards that is expected to be recognized over a weighted-average period of 2.6 years as of September 30, 2023. The Company has recorded stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and nine months ended September 30, 2023 and 2022, respectively, as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Research and development $ 2,033 $ 2,184 $ 6,858 $ 5,547 Selling, general, and administrative 4,796 6,433 18,881 16,791 Total stock-based compensation $ 6,829 $ 8,617 $ 25,739 $ 22,338 The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and nine months ended September 30, 2023 and 2022: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Expected stock price volatility 74 % 78 % 73 % 78 % Expected term of the award (years) 6.2 6.2 6.0 6.2 Risk-free interest rate 4.26 % 3.20 % 3.94 % 2.27 % Weighted average exercise price $ 125.06 $ 70.91 $ 91.38 $ 63.03 Forfeiture rate — % — % — % — % Dividend yield — % — % — % — % 18 Restricted Stock Awards Restricted stock awards ("RSAs") granted to employees vest ratably over a four -year period. The Company granted zero RSAs to employees of the Company during each of the three and nine months ended September 30, 2023 and September 30, 2022, respectively. Number of Shares Weighted Average Grant Date Fair Value Non-vested RSAs as of December 31, 2022 66,600 $ 78.89 Granted — $ — Vested ( 12,649 ) $ 78.89 Surrendered for taxes ( 9,551 ) $ 78.89 Non-vested RSAs as of September 30, 2023 $ 44,400 $ 78.89 There was $ 2.5 million of unrecognized stock-based compensation expense related to employees’ RSAs that is expected to be recognized over a weighted-average period of 1.4 years as of September 30, 2023. The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and nine months ended September 30, 2023 and 2022, as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Selling, general, and administrative $ 437 $ 441 $ 1,305 $ 1,340 Total stock-based compensation $ 437 $ 441 $ 1,305 $ 1,340 Restricted Stock Units Restricted stock units (“RSUs”) granted to employees vest ratably over a four-year period. The Company granted zero and 186,900 RSUs to employees of the Company during the three and nine months ended September 30, 2023, respectively, and zero RSUs during the three and nine months ended September 30, 2022, respectively. Number of Shares Weighted Average Grant Date Fair Value Non-vested RSUs as of December 31, 2022 — Granted 186,900 $ 81.91 Vested — Surrendered or forfeited ( 24,700 ) $ 81.91 Non-vested RSUs as of September 30, 2023 162,200 $ 81.91 There was $ 11.3 million of unrecognized stock-based compensation expense related to employees’ RSU awards that is expected to be recognized over a weighted-average period of 3.4 years as of September 30, 2023. The Company recorded stock-based compensation expense related to RSUs in the condensed consolidated statement of operations for the three and nine months ended September 30, 2023 and 2022, as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Research and Development $ 303 $ — $ 837 $ — Selling, general, and administrative 370 — 998 — Total stock-based compensation $ 673 $ — $ 1,835 $ — 19 Performance-Based Restricted Stock Units Performance-based restricted stock units (“PSUs”) granted to employees vest ratably over two years based upon continued service through the vesting date and the achievement of specific regulatory and commercial performance criteria as determined by the Compensation Committee of the Company’s Board of Directors. The performance criteria are to be completed by the end of the year in which the PSU awards were granted. Each PSU represents the right to receive one share of the Company's common stock upon vesting. The Company recognizes stock-based compensation expense for the fair value of the PSU awards relating to the portion of the awards that are probable of vesting over the service period. On a quarterly basis, management estimates the probable number of PSU’s that would vest until such time that the ultimate achievement of the performance criteria are known. As of September 30, 2023, the Company estimates that 100 % of the PSUs granted will be eligible to vest. The Company granted zero and 60,000 PSUs to employees of the Company during the three and nine months ended September 30, 2023 and zero PSUs during the three and nine months ended September 30, 2022. Number of Shares Weighted Average Grant Date Fair Value Non-vested PSUs as of December 31, 2022 — Granted 60,000 $ 81.91 Vested — Surrendered or forfeited ( 10,000 ) $ 81.91 Non-vested PSUs as of September 30, 2023 50,000 $ 81.91 There was $ 2.9 million of unrecognized stock-based compensation expense related to employees’ PSU awards that is expected to be recognized over a weighted-average period of 1.4 years as of September 30, 2023. The Company recorded stock-based compensation expense related to PSUs in the condensed consolidated statement of operations for the three and nine months ended September 30, 2023 and 2022 as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Selling, general, and administrative $ 373 $ — $ 1,201 $ — Total stock-based compensation $ 373 $ — $ 1,201 $ — Shares remaining available for grant under the Plan were 1,489,488 , with a sublimit for incentive stock options of 30,783 , at September 30, 2023. After the FDA approval of VYJUVEK on May 19, 2023, the Company began capitalizing stock-based compensation associated with the allocation of labor costs related to work performed to manufacture VYJUVEK. For the three and nine months ended September 30, 2023, the Company capitalized $ 410 thousand and $ 522 thousand, respectively, in inventory. Historically, the Company also capitalized the portion of stock-based compensation related to work performed on the construction of our manufacturing facilities. There was zero and $ 162 thousand of stock-based compensation that was capitalized in property and equipment during the three and nine months ended September 30, 2023 and $ 137 thousand and $ 423 thousand of stock-based compensation that was capitalized in property and equipment during the three and nine months ended September 30, 2022, respectively. 11. Gain from Sale of Priority Review Voucher In August 2023, the Company entered into an agreement to sell the rare pediatric disease voucher (“PRV”), which was awarded to the Company in connection with the FDA’s approval of VYJUVEK. The transaction closed in August 2023 and was not subject to any commissions or closing costs. The proceeds of $ 100.0 million from the sale of the PRV were recorded as a gain from sale of priority review voucher on the Company’s condensed consolidated statement of operations as it did not have a carrying value at the time of the sale. 20 12. Subsequent Events The Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require recognition or disclosure. The Company concluded that no subsequent events have occurred, that would require recognition or disclosure in the condensed consolidated financial statements. 21